{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Yu P"],"funding":["NIA NIH HHS","NHLBI NIH HHS","FDA HHS","National Institute for Health Research (NIHR)","U.S. Food and Drug Administration","NINDS NIH HHS","National Institutes of Health","National Institute of Biomedical Imaging and Bioengineering","National Institute on Aging","Science Foundation Arizona"],"pagination":["808-18"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4201941"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["35(4)"],"pubmed_abstract":["The objective of this study was to evaluate the effect of computational algorithm, measurement variability, and cut point on hippocampal volume (HCV)-based patient selection for clinical trials in mild cognitive impairment (MCI). We used normal control and amnestic MCI subjects from the Alzheimer's Disease Neuroimaging Initiative 1 (ADNI-1) as normative reference and screening cohorts. We evaluated the enrichment performance of 4 widely used hippocampal segmentation algorithms (FreeSurfer, Hippocampus Multi-Atlas Propagation and Segmentation (HMAPS), Learning Embeddings Atlas Propagation (LEAP), and NeuroQuant) in terms of 2-year changes in Mini-Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), and Clinical Dementia Rating Sum of Boxes (CD"],"journal":["Neurobiology of aging"],"pubmed_title":["Operationalizing hippocampal volume as an enrichment biomarker for amnestic mild cognitive impairment trials: effect of algorithm, test-retest variability, and cut point on trial cost, duration, and sample size."],"pmcid":["PMC4201941"],"funding_grant_id":["U01 AG010483","R01AG034062","R01 AG011378","U01-HL096917","U19 AG010483","U01 HL096917","NF-SI-0513-10134","R01 AG041851","U01FD003865","U01 AG032438","U01 AG10483","P30 AG010129","R01-AG041851","NF-SI-0508-10123","P50 AG005131","R01-AG037551","R01 AG037551","U01-AG032438","K02 NS067427","R01-AG011378","U01-AG024904","R01 AG034062","U01 FD003865","U01 AG024904","K01 AG030514","SRG 0335-08"],"pubmed_authors":["Stephenson D","Brewer J","Fox NC","Schwarz AJ","Yu P","Hill DL","Jack CR","Coalition Against Major Diseases and the Alzheimer's Disease Neuroimaging Initiative","Cole PE","Wolz R","Sun J"],"additional_accession":[]},"is_claimable":false,"name":"Operationalizing hippocampal volume as an enrichment biomarker for amnestic mild cognitive impairment trials: effect of algorithm, test-retest variability, and cut point on trial cost, duration, and sample size.","description":"The objective of this study was to evaluate the effect of computational algorithm, measurement variability, and cut point on hippocampal volume (HCV)-based patient selection for clinical trials in mild cognitive impairment (MCI). We used normal control and amnestic MCI subjects from the Alzheimer's Disease Neuroimaging Initiative 1 (ADNI-1) as normative reference and screening cohorts. We evaluated the enrichment performance of 4 widely used hippocampal segmentation algorithms (FreeSurfer, Hippocampus Multi-Atlas Propagation and Segmentation (HMAPS), Learning Embeddings Atlas Propagation (LEAP), and NeuroQuant) in terms of 2-year changes in Mini-Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), and Clinical Dementia Rating Sum of Boxes (CD","dates":{"release":"2014-01-01T00:00:00Z","publication":"2014 Apr","modification":"2025-04-22T21:59:59.534Z","creation":"2019-03-27T01:37:57Z"},"accession":"S-EPMC4201941","cross_references":{"pubmed":["24211008"],"doi":["10.1016/j.neurobiolaging.2013.09.039"]}}